Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7748021 | 0.70 | NPC1 (0.37) | — | |
| SCHEMBL5986706 | 0.66 | — | — | |
| SCHEMBL15987061 | 0.66 | EPHX2 (0.34) | — | |
| SCHEMBL16749759 | 0.64 | TSHR (0.32) | — | |
| SCHEMBL2606649 | 0.62 | — | — | |
| SCHEMBL191351 | 0.62 | NPC1 (0.45) | — | |
| SCHEMBL22000103 | 0.62 | DRD3 (0.38) | DRD3 | |
| SCHEMBL17682152 | 0.61 | EPHX2 (0.32) | — | |
| SCHEMBL17356736 | 0.61 | — | — | |
| SCHEMBL192534 | 0.61 | NPC1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745320-B2 | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2017-08-29 | — | — | US | disclosed |
| US-20160289236-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-10-06 | — | — | US | disclosed |
| US-20150336982-A1 | Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof | SHANGHAI CHEMEXPLORER CO., LTD. (CN) | 2015-11-26 | — | — | US | disclosed |
| EP-2947084-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Chemexplorer Co., Ltd. (CN) | 2015-11-25 | — | — | EP | disclosed |
| WO-2015074135-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2015-05-28 | — | — | WO | disclosed |
| WO-2014111037-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海昀怡健康管理咨询有限公司 (CN) | 2014-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336982-A1 | Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof | JAK1, JAK2, JAK3 | DRD3 4690/4885 |
| US-20160289236-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | DRD3 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.